Verano Holdings (VRNO) Cash from Investing Activities (2021 - 2026)
Verano Holdings (VRNO) posted quarterly Cash from Investing Activities of -$14.9 million for Q1 2026, down 212.45% year-over-year from $13.3 million in Q1 2025, and down 49.56% quarter-over-quarter from -$10.0 million in Q4 2025.
Verano Holdings (VRNO) Cash from Investing Activities (2021 - 2026) Analysis & Trends
Verano Holdings (VRNO) has reported Cash from Investing Activities for 6 consecutive years, with -$14.9 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Cash from Investing Activities fell 212.45% year-over-year to -$14.9 million; the TTM figure through Mar 2026 stood at -$42.7 million (up 66.7% YoY), while the FY2025 annual figure was -$32.6 million, up 75.53% from the prior year.
- Cash from Investing Activities eased to -$14.9 million in Q1 2026 per VRNO's latest filing, from -$10.0 million in the prior quarter.
- Across five years, Cash from Investing Activities topped out at -$4.8 million in Q1 2025 and bottomed at -$92.6 million in Q3 2024.
- Historically, Cash from Investing Activities has averaged -$24.9 million across 5 years, with a median of -$10.4 million in 2025.
- Annual changes were most pronounced in 2023 — Cash from Investing Activities jumped 92.25% — and 2024, when it tumbled 830.65%.
- Verano Holdings' Cash from Investing Activities stood at -$22.6 million in 2022, then soared by 56.45% to -$9.8 million in 2023, then dropped by 26.17% to -$12.4 million in 2024, then increased by 19.61% to -$10.0 million in 2025, then plunged by 49.56% to -$14.9 million in 2026.
- Business Quant data shows VRNO's Cash from Investing Activities at -$14.9 million in Q1 2026, -$10.0 million in Q4 2025, and -$7.5 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.51 Bn | 43.55 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.52 Bn | 39.86 Bn | 2.15 Bn | -491.00 Mn |
| 3 | Zoetis | 32.43 Bn | 30.75 Bn | 1.05 Bn | -300.00 Mn |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn | -550.24 Mn |
| 5 | United Therapeutics | 21.87 Bn | 19.21 Bn | 683.80 Mn | 87.50 Mn |
| 6 | Viatris | 18.98 Bn | 18.09 Bn | 1.46 Bn | -51.60 Mn |
| 7 | Neurocrine Biosciences | 15.43 Bn | 15.04 Bn | 935.80 Mn | -135.40 Mn |
| 8 | Elanco Animal Health | 12.02 Bn | 11.49 Bn | 798.00 Mn | -110.00 Mn |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - | - |
| 10 | Verano Holdings | 449.04 Mn | 363.85 Mn | 99.70 Mn | -11.85 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -11.85 Mn |
| Jun 30, 2026 | -11.85 Mn |
| Mar 31, 2026 | -14.91 Mn |
| Mar 31, 2026 | -14.91 Mn |
| Dec 31, 2025 | -9.97 Mn |
| Dec 31, 2025 | -9.97 Mn |
| Sep 30, 2025 | -7.45 Mn |
| Sep 30, 2025 | -7.45 Mn |
| Jun 30, 2025 | -10.41 Mn |
| Jun 30, 2025 | -10.41 Mn |
| Mar 31, 2025 | -4.77 Mn |
| Mar 31, 2025 | -4.77 Mn |
| Dec 31, 2024 | -12.40 Mn |
| Dec 31, 2024 | -12.40 Mn |
| Sep 30, 2024 | -92.64 Mn |
| Sep 30, 2024 | -92.64 Mn |
| Jun 30, 2024 | -18.52 Mn |
| Jun 30, 2024 | -18.52 Mn |
| Mar 31, 2024 | -9.70 Mn |
| Mar 31, 2024 | -9.70 Mn |